206 related articles for article (PubMed ID: 32395117)
1. Preclinical Studies of the Off-Target Reactivity of AFP
Cai L; Caraballo Galva LD; Peng Y; Luo X; Zhu W; Yao Y; Ji Y; He Y
Front Immunol; 2020; 11():607. PubMed ID: 32395117
[TBL] [Abstract][Full Text] [Related]
2. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.
Zhu W; Peng Y; Wang L; Hong Y; Jiang X; Li Q; Liu H; Huang L; Wu J; Celis E; Merchen T; Kruse E; He Y
Hepatology; 2018 Aug; 68(2):574-589. PubMed ID: 29443377
[TBL] [Abstract][Full Text] [Related]
3. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
Front Immunol; 2020; 11():623. PubMed ID: 32425926
[TBL] [Abstract][Full Text] [Related]
4. TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma.
Hussein MS; Li Q; Mao R; Peng Y; He Y
Front Immunol; 2023; 14():1114770. PubMed ID: 37215108
[TBL] [Abstract][Full Text] [Related]
5. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.
Sun L; Guo H; Jiang R; Lu L; Liu T; He X
Tumour Biol; 2016 Jan; 37(1):799-806. PubMed ID: 26250457
[TBL] [Abstract][Full Text] [Related]
6. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
Cameron BJ; Gerry AB; Dukes J; Harper JV; Kannan V; Bianchi FC; Grand F; Brewer JE; Gupta M; Plesa G; Bossi G; Vuidepot A; Powlesland AS; Legg A; Adams KJ; Bennett AD; Pumphrey NJ; Williams DD; Binder-Scholl G; Kulikovskaya I; Levine BL; Riley JL; Varela-Rohena A; Stadtmauer EA; Rapoport AP; Linette GP; June CH; Hassan NJ; Kalos M; Jakobsen BK
Sci Transl Med; 2013 Aug; 5(197):197ra103. PubMed ID: 23926201
[TBL] [Abstract][Full Text] [Related]
8. Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
Docta RY; Ferronha T; Sanderson JP; Weissensteiner T; Pope GR; Bennett AD; Pumphrey NJ; Ferjentsik Z; Quinn LL; Wiedermann GE; Anderson VE; Saini M; Maroto M; Norry E; Gerry AB
Hepatology; 2019 May; 69(5):2061-2075. PubMed ID: 30561769
[TBL] [Abstract][Full Text] [Related]
9. Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy.
Li Z; Gong H; Liu Q; Wu W; Cheng J; Mei Y; Chen Y; Zheng H; Yu X; Zhong S; Li Y
Immunology; 2020 Apr; 159(4):384-392. PubMed ID: 31849039
[TBL] [Abstract][Full Text] [Related]
10. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.
Liu H; Xu Y; Xiang J; Long L; Green S; Yang Z; Zimdahl B; Lu J; Cheng N; Horan LH; Liu B; Yan S; Wang P; Diaz J; Jin L; Nakano Y; Morales JF; Zhang P; Liu LX; Staley BK; Priceman SJ; Brown CE; Forman SJ; Chan VW; Liu C
Clin Cancer Res; 2017 Jan; 23(2):478-488. PubMed ID: 27535982
[TBL] [Abstract][Full Text] [Related]
11. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.
Soon CF; Zhang S; Suneetha PV; Antunes DA; Manns MP; Raha S; Schultze-Florey C; Prinz I; Wedemeyer H; Sällberg Chen M; Cornberg M
Front Immunol; 2019; 10():2076. PubMed ID: 31552033
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
[TBL] [Abstract][Full Text] [Related]
14. TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan AR; Chaipan C; Winkelbach K; Wimberger S; Jeong JS; Joshi B; Stein RB; Underwood D; Castle JC; van Dijk M; Seibert V
Front Immunol; 2019; 10():2501. PubMed ID: 31695703
[TBL] [Abstract][Full Text] [Related]
15. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.
Butterfield LH; Meng WS; Koh A; Vollmer CM; Ribas A; Dissette VB; Faull K; Glaspy JA; McBride WH; Economou JS
J Immunol; 2001 Apr; 166(8):5300-8. PubMed ID: 11290817
[TBL] [Abstract][Full Text] [Related]
16. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.
Butterfield LH; Koh A; Meng W; Vollmer CM; Ribas A; Dissette V; Lee E; Glaspy JA; McBride WH; Economou JS
Cancer Res; 1999 Jul; 59(13):3134-42. PubMed ID: 10397256
[TBL] [Abstract][Full Text] [Related]
17. T-cell Receptors Engineered
Sharma P; Harris DT; Stone JD; Kranz DM
Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
[TBL] [Abstract][Full Text] [Related]
18. High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells.
Kang S; Li Y; Bao Y; Li Y
Front Med; 2019 Feb; 13(1):69-82. PubMed ID: 30725257
[TBL] [Abstract][Full Text] [Related]
19. A third sublineage of avian T cells can be identified with a T cell receptor-3-specific antibody.
Char D; Sanchez P; Chen CL; Bucy RP; Cooper MD
J Immunol; 1990 Dec; 145(11):3547-55. PubMed ID: 2123221
[TBL] [Abstract][Full Text] [Related]
20. Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E.
Soon CF; Behrendt P; Todt D; Manns MP; Wedemeyer H; Sällberg Chen M; Cornberg M
J Hepatol; 2019 Oct; 71(4):673-684. PubMed ID: 31203151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]